Research | Clinical Trials | Clinical Trial Details Page

Cannabinoids, Neural Synchrony, and Information Processing

Conditions

Cannabis | Psychotic Disorders

Trial Phase

Phase 1

Trial Purpose and Description

Trial Purpose

The study examines the effects of delta-9-tetrahydrocannabinol (Δ9-THC), the principal active ingredient of cannabis, on neural synchrony. Neural synchrony is studied using electroencephalography (EEG).


Participation Guidelines

Age:
18 Years - 55 Years
Gender:
Both

Eligibility Criteria


Inclusion Criteria:

- Men and women aged 18 and 55 years (extremes included) on the day of the first
dosing.

- Exposed to cannabis at least once.

Exclusion Criteria:

1. Cannabis na7ve

2. Positive pregnancy screen during screening

3. Hearing deficits
Sponsor:
National Institute on Drug Abuse (NIDA)
Yale University
Dates:
April 2008
Last Updated:
March 11, 2013
Study HIC#:
0803003638

Clinicaltrials.gov ID: NCT00708994